Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...

Lawmakers have focused on the high cost of diabetes drugs. The announcement will make state-branded insulin available two ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...

California will offer CalRx-branded biosimilar insulin glargine pens for $11 per pen beginning January 1, 2026.

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

California will soon become the first state to offer its own affordable insulin, with Gov. Gavin Newsom announcing that CalRx ...

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector ...